openwiki-wiki/sources/web-search.md

# Web Search Evidence

> Connector: `web-search-1` (Tavily). This page records compact, relevant evidence from Tavily pulls; search results are discovery leads, not vendor-confirmed announcements. Latest pull: 2026-07-27 18:04 UTC.

## 2026-07-26 pull

### 3D spheroid automation and assay standardization — source-backed

- **Nature, published 2026-07-21:** [Automation of 3D liver spheroid generation and acetaminophen dose–response on the MO:BOT enhances assay robustness and precision](https://www.nature.com/articles/s41598-026-58939-4). The article describes an integrated automated workflow for generating and maintaining 3D liver spheroids and links standardization, reproducibility, and consistent morphology/function to broader adoption of 3D human-cell models in preclinical research.
- **Robin relevance:** strong application signal for CelVivo-style spheroid workflows and pharma assay discussions, but the result is about MO:BOT rather than CelVivo. Treat as a competitive/application watchlist lead, not a CelVivo product claim.
- **Related result:** the same Nature article appeared in the Cellink BIO X and CellShot/CellPick searches; the snippets characterize 3D bioprinters as useful for complex ECM-embedded constructs but generally narrower than an end-to-end maintenance/readout workflow.

### Organ-on-chip and preclinical translation — watchlist

- **Nature, published 2026-07-23:** [Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism](https://www.nature.com/articles/s44385-026-00099-1). Tavily's result highlights intestinal first-pass metabolism and pharmacokinetic differences for orally administered drugs.
- **GeneOnline, published 2026-07-26:** [Next-Gen Preclinical Translation: Non-Animal Methods, Humanized Mouse Models, and AI Integration](https://www.geneonline.com/bio-asia-taiwan-2026-next-gen-preclinical-translation-july-007-report/). The snippet frames organ-on-a-chip, NAMs, humanized models, and predictive AI as part of current preclinical translation work.
- These are relevant to Robin's organ-on-chip/pharma lane, but the pull provides no customer, vendor, or regulatory action. Keep as watchlist evidence.

### 3Brain / neuroscience search lane — no direct product confirmation

- The strongest result was a 2026-07-24 *Scientific Reports* article on a portable semi-dry EEG device for brain-computer-interface applications ([Nature link](https://www.nature.com/articles/s41598-026-52672-8)); it does not identify 3Brain CorePlate or MEA chips. Do not promote it as 3Brain evidence.

### Cellink, Femtobiomed, and workflow tooling

- The pull produced no credible direct Cellink BIO X/BIONOVA X/Lumen X announcement, no CellShot/CellPick/TriArm result, and no Hermes/OpenWiki/RAGFlow ecosystem result.
- The CellShot search returned a Cellares/Papillon automation partnership, but this is unrelated to Femtobiomed's CellShot product and is excluded from synthesis.

## Evidence handling

- Search results are single-source discovery evidence; vendor-specific claims require direct vendor or independent corroboration before being labeled `confirmed` or `source-backed`.
- Generic bioprinting, cell-therapy manufacturing, unrelated EEG, and off-topic AI results from this pull were discarded as noise under Robin's scope.

## Source coverage

- Fetched: 2026-07-26T17:39:11Z
- Queries: 10
- Instance: `web-search-1`
- Raw evidence: `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`

---

## 2026-07-26 18:07 pull

Second Tavily pull on the same day (same 10-query lane). Three lanes produced material new evidence (China regulatory, organ-on-chip/CDMO, Hermes agent model eval). CelVivo / 3Brain / Cellink lanes re-surfaced the earlier Nature papers with Tavily's *answer text* mis-attributing vendor names — flagged below.

### China CDE cell & gene therapy classification — source-backed

- **cisema.com, 2026-07-24:** [China CDE Defines Classification Rules for Cell & Gene Therapy Drugs](https://cisema.com/news/china-cell-gene-therapy-classification). China's Center for Drug Evaluation (CDE) under the National Medical Products Administration published technical guidelines defining scope and classification of cell therapy medicinal products and gene therapy medicinal products; aims to standardize CMC planning and regulatory engagement.
- **Robin relevance:** direct read for the Chinese pharma R&D / CDMO / biotech customer base. Single credible source — keep as `source-backed` until corroborated by an NMPA/CDE-direct release. Promoted to `/themes.md` row `china-cde-cell-gene-therapy-rules-2026` and `/commitments.md` as a verification item.
- Lighter signals in this lane: Roots Analysis [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html) (2026-07-24); Frontiers [pilot study of nebulized 3D-cultured MSC-derived extracellular vesicles](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1809451/full) (2026-07-24); PharmaSalmanac [Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes](https://www.pharmasalmanac.com/articles/stem-cell-therapies-close-to-transforming-promise-into-real-patient-outcomes) (2026-07-22). Application-domain signal only — folded into the existing `class-organoid-3d-bioprinting` row evidence.

### Organ-on-chip / CDMO collaboration / ADLM 2026 — source-backed

- **BioSpace, 2026-07-24:** [Phillips Medisize to Present Strategies for Scaling Complex In Vitro Diagnostic (IVD) Builds Through Structured CDMO Collaboration at ADLM 2026](https://www.biospace.com/press-releases/phillips-medisize-to-present-strategies-for-scaling-complex-in-vitro-diagnostic-ivd-builds-through-structured-cdmo-collaboration-at-adlm-2026). Top score (0.413) — frames CDMO collaboration as the path to scaling complex IVD / organ-on-chip workflows.
- **BioSpace, 2026-07-24:** [AcroCyte Therapeutics Awarded ARPA-H Funding to Advance Scalable Human Organoid Technologies](https://www.biospace.com/press-releases/acrocyte-therapeutics-awarded-arpa-h-funding-to-advance-scalable-human-organoid-technologies). 0.215 score. ARPA-H backing for scalable human-organoid platforms — application-domain signal for CelVivo-class bioreactor positioning.
- **Nature, 2026-07-24:** [Engineering etiology-aligned in vitro models of human vessels](https://www.nature.com/articles/s41378-026-01397-9). 0.165 score. Disease-specific in vitro vessel models — organoid/3D-cell-culture adjacent.
- **BioSpace, 2026-07-23:** [Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026](https://www.biospace.com/press-releases/roche-showcases-intelligent-lab-solutions-and-high-precision-instruments-at-adlm-2026-to-help-laboratories-address-workforce-and-workflow-challenges). 0.151 score. Industry context, not vendor-anchored to Robin's 4 lines.

### Hermes Agent best-models eval — source-backed (workflow tooling, low priority)

- **haimaker.ai, 2026-07-23:** [Best Models for Hermes Agent (July 2026): Tested & Ranked](https://haimaker.ai/blog/best-models-for-hermes-agent). 0.731 score. Third-party ranking of LLMs for Hermes Agent usage — Robin-relevant as the daily-driver stack. Folds into the existing `MiniMax-m3` theme row last-seen.
- **Reddit, 2026-07-22:** [What are you USE CASES for Hermes Agent?](https://www.reddit.com/r/hermesagent/comments/1v34auv/what_are_you_use_cases_for_hermes_agent). 0.424 score. User-driven Hermes use cases; not a vendor-anchored signal.
- **Data-quality flag:** Tavily's synthesized *answer* for this lane hallucinated detail ("streaming robustness, REPL UX improvements, and provider hardening") — none of those bullets appear in the haimaker article. Treat Tavily's answer text as untrusted.

### CelVivo / 3Brain / Cellink / CellShot lanes — same Nature results, Tavily answer text mis-attributed

- **CelVivo ClinoReactor / Cellink BIO X:** the Nature [MO:BOT liver-spheroid automation paper](https://www.nature.com/articles/s41598-026-58939-4) reappears at score 0.402 (CelVivo lane) and 0.074 (Cellink lane). Tavily's answer text describes MO:BOT but labels the platform "ClinoReactor" / "BIO X" — vendor attribution is **wrong**. Treat the result as the MO:BOT paper, not a CelVivo or Cellink product claim.
- **3Brain CorePlate MEA:** the Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187. Tavily's answer text labels it "3Brain CorePlate MEA 2026" — this is wrong; the paper is about an EEG headset, not 3Brain's MEA chips. Do not promote as 3Brain evidence.
- **CellShot / CellPick:** Cellares–Papillon partnership (Cellares is unrelated to Femtobiomed) and CCDx liquid biopsy — no direct Femtobiomed result in either pull.
- **CelVivo installed-base:** no direct result; pull dominated by Cepheid GeneXpert noise. Query phrasing needs a vendor-name anchor to retrieve CelVivo-specific results.

### OpenWiki / RAGFlow / agent-memory-wiki lanes — Tavily recall broken

- "OpenWiki connectors Tavily RAGFlow 2026" returned SmartBall X pipeline inspection, AWWA ACE26, insurance backchat, helicopter partnership, OLED manufacturing equipment, and fashion-show slides. None of the 8 results touches Robin's actual stack (OpenWiki / Gitea / Wiki.js / RAGFlow / NocoDB / SeaFile). Skip until the query is rephrased.
- "Agent personal memory wiki 2026" returned an Australian enterprise data-AI survey (0.403), a LangChain4j self-building-agent experiment (0.168), and ad-agency awards — no direct personal-wiki / OpenWiki-self evidence. Adjacent only.

## Source coverage (cumulative)

- Pull 1: fetched 2026-07-26T17:39:11Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
- Pull 2: fetched 2026-07-26T18:07:27Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json`
- Pull 3: fetched 2026-07-26T18:16:21Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json`
- Queries: pull 1 + pull 2 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
- Instance: `web-search-1`

---

## 2026-07-26 18:16 pull

Third Tavily pull on the same day, after the 2026-07-27 `~/.openwiki/INSTRUCTIONS.md` scope was loaded. The query lane was narrowed from 10 vendor-mixed queries to **6 vendor-anchored queries**, dropping the China-cell-therapy regulation lane (now stale-pinned via `/commitments.md`), the Hermes Agent / MiniMax M3 daily-driver lane, and the OpenWiki/RAGFlow/agent-memory lanes (the latter two were already noise per the prior pulls).

### Queries and top results

| Query | Top hits | Score | Vendor-anchor |
| --- | --- | --- | --- |
| `CelVivo ClinoReactor spheroid new paper 2026` | Nature MO:BOT liver-spheroid automation paper (re-mention); Patient-Derived Tumor Organoids for personalizing cancer treatment; CCDx whole-cell genomic profiling | 0.44 / 0.11 / 0.05 | no — MO:BOT, not CelVivo; organoid application only |
| `3Brain CorePlate MEA neuron 2026` | News-Medical.net "New imaging platform tracks hundreds of neurons at unprecedented depths"; BioSpace brain-remodeling-during-adolescence; MobiHealthNews first able-bodied BCI recipients | 0.20 / 0.10 / 0.08 | no — generic neuroscience imaging, not 3Brain CorePlate |
| `Cellink BIO X bioprinter clinical 2026` | Roche ADLM 2026 intelligent lab solutions; 10x Genomics CLIA lab + Cleveland Clinic; Massive Bio FOMAT cancer prescreening | 0.11 / 0.09 / 0.07 | no — industry context; 10x / Massive Bio unrelated to Cellink |
| `organoid-on-chip pharmacology 2026` | AcroCyte Therapeutics ARPA-H funding for scalable human-organoid tech (re-mention, score up to 0.617 from 0.215); Patient-Derived Tumor Organoids; Nature MO:BOT liver-spheroid | 0.62 / 0.41 / 0.35 | no — AcroCyte is application, not one of Robin's 4 vendors |
| `CellShot CellPick bioprinter research 2026` | Cellares–Papillon PPL-001 automation partnership (re-mention); CCDx whole-cell genomic profiling; Genetic Engineering AI protein-engineering for biomanufacturing | 0.17 / 0.14 / 0.08 | no — Cellares/Papillon unrelated to Femtobiomed |
| `lab automation assay workflow news 2026` | Roche ADLM 2026; Nature MO:BOT liver-spheroid; Cepheid third-generation GeneXpert at ADLM 2026 | 0.82 / 0.74 / 0.56 | no — Roche/Cepheid industry context, not vendor-anchored |

### Synthesis result

- **No new vendor-anchored evidence** — every query's top hit is either (a) application/organoid-level without naming Robin's 4 vendors, (b) a re-mention of an item already in the 17:38 or 18:07 pull, or (c) an unrelated industry/competitor brand (Roche, Cepheid, 10x, Cellares, Massive Bio, CCDx).
- **AcroCyte ARPA-H** reappears at 0.617 (up from 0.215 in the 18:07 pull). Same item, stronger score — the existing `/themes.md` `class-organoid-3d-bioprinting` row already covers it via the ARPA-H funding evidence; no new row needed.
- **Tavily answer-text vendor mis-attribution continues.** The `CelVivo ClinoReactor spheroid new paper 2026` answer text describes MO:BOT but labels it "ClinoReactor"; the `3Brain CorePlate MEA neuron 2026` answer text points at generic brain-imaging news without anchoring to CorePlate. Treat Tavily answer text as untrusted and only the underlying URLs as evidence.
- **Dropped lanes** (vs. pull 2): `China cell therapy 3D bioprinting regulation 2026` (China CDE item still anchored in `/commitments.md` as `china-cde-cell-gene-therapy-rules-2026`); `Hermes Agent MiniMax M3 changelog 2026` (already in `/themes.md` `MiniMax-m3` row); `OpenWiki connectors Tavily RAGFlow 2026` (noise); `agent personal memory wiki 2026` (noise). Existing rows on `/themes.md` and `/commitments.md` are unchanged because their evidence sources (Tavily pull 2, HN pull 18:00) are still on disk and referenceable.

### Coverage note for next update

The China CDE regulatory lane is no longer being refreshed on every Tavily pull. The existing `/commitments.md` item pins it as `source-backed` with one credible cisema.com source. If a future Tavily or HN pull surfaces an NMPA / CDE-direct corroboration, promote from watchlist to `source-backed` and move into `/themes.md` as a confirmed row.
ll

Fourth Tavily pull on the 2026-07-27 cycle, run as a stand-alone `openwiki personal --update` source ingest. All 10 queries were re-run. Two lanes produced genuinely new material evidence (CelVivo / ClinoReactor vendor-anchored signal; Hermes Agent v0.19 Quicksilver workflow-tooling release). One lane (3D-bioprinted-organoid reviews) added supporting evidence to the existing `class-organoid-3d-bioprinting` row. The Tavily answer-text mis-attribution pattern recurred on the 3Brain, Cellink, and MiniMax-M3 lanes — flagged again below.

### CelVivo ClinoReactor + TheWell Bioscience xeno-free workflow — source-backed

This is the **first vendor-anchored CelVivo signal in any Tavily pull**. Prior pulls returned only MO:BOT or generic organoid content. Three TheWell Bioscience pages published in the 2026-07-21 / 2026-07-23 / 2026-07-25 window all reference "CelVivo ClinoReactor™" by name in their product content:

- **TheWell Bioscience, 2026-07-21:** [Cell Culture Media (Xeno-Free)](https://www.thewellbio.com/product-category/xeno-free-cell-culture-media). Score 0.591. "An all-in-one xeno-free kit with optimized matrix, medium, and reagents … 3D neural stem cell culture. 2026 TheWell Bioscience Inc. CelVivo ClinoReactorTM". Position: ClinoReactor as the vessel in a complete xeno-free workflow.
- **TheWell Bioscience, 2026-07-25:** [Xeno-Free Stem Cell Culture Product Guide](https://www.thewellbio.com/xeno-free-stem-cell-culture-guide). Score 0.585. Comprehensive product guide featuring validated applications and optimized workflows that name ClinoReactorTM as part of the integrated workflow.
- **TheWell Bioscience, 2026-07-23:** [White Paper — Culture Apical-Out Organoids with Xeno-Free VitroGel System](https://www.thewellbio.com/white-paper_culture-apical-out-organoids-with-xeno-free-vitrogel-system). Score 0.213. "3D Cell Culture Scale-up by Using VitroGel® Hydrogel Matrix embedding in CelVivo ClinoReactorTM" — directly frames ClinoReactor as the scale-up vessel for apical-out organoids.
- **TheWell Bioscience, 2026-07-21:** [Culture Apical-Out Organoids with Xeno-Free VitroGel® System (on-demand webinar)](https://www.thewellbio.com/white-papers/culture-apical-out-organoids-with-xeno-free-with-vitrogel). Score 0.179. Companion webinar to the white paper.

**Tavily answer-text quality is honest on this lane** — the response correctly names TheWell Bioscience's xeno-free product and references ClinoReactor, not hallucinated vendor attributions.

**Robin relevance:** high. This is the only Tavily pull where CelVivo ClinoReactor has been named by a vendor-adjacent (media/reagent) partner, with three same-week pages and a white paper. Possible interpretations: (a) CelVivo-TheWell co-marketing agreement; (b) TheWell is using ClinoReactor as a reference platform for their own product positioning; (c) organic partner content. Promoted to `/commitments.md` as `celvivo-clinoreactor-thewell-bioscience-xeno-free` with status "verify on next CelVivo vendor check". The new evidence is also folded into the `class-organoid-3d-bioprinting` row.

### Hermes Agent v0.19 "Quicksilver" Release — source-backed (workflow tooling, low priority)

The `Hermes Agent MiniMax M3 changelog 2026` query returned a material release note for **Hermes Agent v0.19**, the "Quicksilver" release from Nous Research. Note: Tavily's answer text hallucinated attribution to "MiniMax M3" (the underlying subject is Hermes Agent, not the M3 model). The underlying URLs confirm the release:

- **Instagram (techkwon reel), no exact date in 2026-07:** [Hermes Agent 0.19 Quicksilver Release notes](https://www.instagram.com/reel/DbB2yomkss8). Score 0.573. Names the v0.19 features: first-token delay 4.3s → 0.9s, profile routing, live subagent, delivery ledger, 1Password/Bitwarden integration.
- **Instagram (Nous Research reel), 2026-07-25:** [Hermes Agent v0.19 Quicksilver Release](https://www.instagram.com/reel/DbGaGsoqUUx). Score 0.475. Nous Research's own channel describes the first-token-delay fix and the wider v0.19 feature set.
- **Reddit r/hermesagent, 2026-07-22:** [What are your USE CASES for Hermes Agent?](https://www.reddit.com/r/hermesagent/comments/1v34auv/what_are_you_use_cases_for_hermes_agent). Score 0.424. 83 upvotes / 113 comments — community discussion of Hermes Agent usage patterns.
- **regolo.ai, 2026-07-27:** [TencentDB Agent Memory: Hermes & OpenClaw Setup Guide](https://regolo.ai/tencentdb-agent-memory-the-complete-guide-to-persistent-memory-for-hermes-and-openclaw-with-zero-data-retention). Score 0.120. Third-party persistent-memory backend for Hermes Agent — adjacent integration signal, not a Nous release item.

**Robin relevance:** Hermes Agent is Robin's daily-driver stack per `~/.openwiki/INSTRUCTIONS.md`. v0.19's profile routing, live subagent, and 1Password/Bitwarden integration are story-worthy shifts. New theme row `hermes-agent-v0-19-quicksilver` added to `/themes.md`; this is distinct from the existing `MiniMax-m3` row, which is about the M3 model itself.

**MCP 2026-07-28 revision finalization (adjacent watchlist):** [The Register, 2026-07-23](https://www.theregister.com/devops/2026/07/23/model-context-protocol-prepares-to-break-with-its-stateful-past/5276722) — score 0.059. MCP maintainers plan to finalize the 2026-07-28 protocol revision, not backward-compatible, breaks with stateful past. Single-source, low Tavily score, but directly relevant to OpenWiki's MCP server architecture. Folded into the new `hermes-agent-v0-19-quicksilver` theme row's Evidence column rather than spawning a separate row.

### 3D bioprinted organoid reviews + Pluristyx hepatocyte manufacturing — folded into `class-organoid-3d-bioprinting`

Two same-week review papers and one iPSC + aerospace clinical-grade hepatocyte manufacturing press release re-anchor the existing application-domain theme row:

- **Oxford Academic, 2026-07-27:** [Three-dimensional bioprinted organoids: advances and applications](https://academic.oup.com/rb/article/8722305). Score 0.107. Review of bioprinting techniques, bio-ink development, and clinical applications. Application-domain evidence, not vendor-anchored.
- **Sage journals, 2026-07-22:** [Three-Dimensional Bioprinting-Enabled Organoids](https://journals.sagepub.com/doi/10.1177/19373368261469463). Score 0.125. Review of major 3D bioprinting technologies (extrusion, droplet, photopolymerization). Application-domain evidence.
- **GlobeNewswire via Manila Times, 2026-07-27:** [Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications](https://www.manilatimes.net/2026/07/27/tmt-newswire/globenewswire/pluristyx-partners-with-leading-regenerative-medicine-and-aerospace-pioneers-to-standardize-clinical-grade-hepatocyte-manufacturing-for-space-and-earth-applications/2392136). Score 0.219. Pluristyx (iPSC + genetically engineered solutions) partnering with aerospace players on clinical-grade hepatocyte manufacturing. Adjacent to ClinoReactor liver-spheroid use cases.

All three items fold into the existing `class-organoid-3d-bioprinting` row. Last seen refreshed to 2026-07-27; evidence count increased.

### 3Brain / Cellink / CellShot / installed-base / RAGFlow lanes — no new vendor-anchored evidence; Tavily answer-text mis-attribution recurs

- **3Brain CorePlate MEA 2026:** the Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187. Tavily's answer text again labels it "3Brain CorePlate MEA 2026" validated in a brain-computer-interface study — the underlying paper is about a portable EEG headset, **not 3Brain MEA chips**. Do not promote as 3Brain evidence. Other hits in this lane (News-Medical FlatMux imaging, Precision Neuro BCI, BioTechniques bi-weekly) are application-domain only.
- **Cellink BIO X bioprinter 2026:** no direct Cellink result. Top hits are Velo3D Livermore campus, Lumafield Mars X-ray inspection, AI protein engineering model, Repligen–BioLife ($1.5bn cell-therapy acquisition). All unrelated to Cellink BIO X / BIONOVA X / Lumen X. Application-domain only.
- **CellShot / CellPick bioprinter 2026:** no Femtobiomed result. Cellares–Papillon PPL-001 partnership (Cellares is unrelated to Femtobiomed) at score 0.201, CCDx whole-cell genomic profiling at 0.164, Nature MO:BOT paper re-mention at 0.074. Tavily answer text honestly says "The CellShot CellPick bioprinter 2026 is not directly mentioned in the provided data sources."
- **labs CelVivo ClinoStar installed base 2026:** no direct result. Cepheid GeneXpert third-generation ADLM 2026 (score 0.112) dominates the top slot and is unrelated to CelVivo installed-base. Query phrasing continues to drift toward competitor/molecular-diagnostic content.
- **China cell therapy 3D bioprinting regulation 2026:** re-anchors the existing `/commitments.md` `china-cde-cell-gene-therapy-rules-2026` item. Top result: Roots Analysis [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html) (0.669) re-mentioning Merck's $11.3B Bio-Techne acquisition. Second hit: cisema.com (0.666) — the same China CDE source as the 2026-07-26 18:07 pull.
- **OpenWiki connectors Tavily RAGFlow 2026:** Tavily recall still broken. Returns AWWA ACE26 SmartBall X pipeline inspection, MBT cybersecurity coverage, Seatrade S-100, OpenTug agricultural shipping, iVeena FDA meeting, RightShip–NorthStandard, LEO satellite scaling, Tokyo fashion show. None of the 8 results touches Robin's actual stack.
- **agent personal memory wiki 2026:** iTnews State of Data & AI 2026 (Australian enterprise agentic AI, 0.403), LangChain4j self-building-agent (0.168), Times of Israel Cursor CVE-2026-48124 (0.121), Ad Age small-agency awards (0.103 / 0.103 / 0.083 / 0.082), MCP 2026-07-28 revision (0.059, see above). Only the MCP item is actionable; the rest is noise or adjacent to Robin's stack without direct relevance.

### Synthesis result

- **Two new scope-aligned findings:** (a) CelVivo ClinoReactor + TheWell Bioscience xeno-free workflow (vendor-anchored, first time in any Tavily pull); (b) Hermes Agent v0.19 Quicksilver (workflow tooling, source-backed).
- **Two supporting application-domain items** folded into the existing `class-organoid-3d-bioprinting` row: two 3D-bioprinted organoid review papers (Oxford 2026-07-27, Sage 2026-07-22) and Pluristyx iPSC + aerospace hepatocyte manufacturing press release (2026-07-27).
- **Tavily answer-text mis-attribution pattern persists** on the 3Brain and Cellink lanes; this is the third pull in a row where the answer text names a vendor that is not actually in the underlying source. Continue treating Tavily answer text as untrusted; only the underlying URLs are evidence.
- **OpenWiki / RAGFlow lane** still produces zero relevant results after four pulls. Consider dropping this lane from future Tavily runs unless the query is rephrased to anchor on product names (e.g. "RAGFlow 0.x release notes" instead of "OpenWiki connectors Tavily RAGFlow").

## Source coverage (cumulative)

- Pull 1: fetched 2026-07-26T17:39:11Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
- Pull 2: fetched 2026-07-26T18:07:27Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json`
- Pull 3: fetched 2026-07-26T18:16:21Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json`
- Pull 4: fetched 2026-07-27T18:04:46Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-27T18-04-01-259Z/web-search-results.json`
- Pull 5: fetched 2026-07-28T18:04:26Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-28T18-03-43-560Z/web-search-results.json`
- Queries: pulls 1, 2, 4, 5 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
- Instance: `web-search-1`

---

## 2026-07-28 18:04 pull

Fifth Tavily pull, run as a stand-alone `openwiki personal --update` source ingest. All 10 queries re-run. Two lanes produced genuinely new material evidence (China Order No. 818 regulatory shift; LLM Wiki + OKF shared-memory architecture cluster). The China CDE classification item, CelVivo/TheWell partnership, and Hermes v0.19 Quicksilver rows were not re-anchored in this pull — they remain pinned via `/commitments.md` and the `hermes-agent-v0-19-quicksilver` / `china-cde-cell-gene-therapy-rules-2026` theme rows. Tavily answer-text mis-attribution continues on the 3Brain, Cellink, and Hermes lanes.

### China Order No. 818 — accelerated clinical-translation pathway — source-backed

This is a **new Chinese regulatory signal distinct from the existing CDE classification item**. Order No. 818 (effective 2026-05-01) creates an accelerated pathway for advanced biomedical technologies — including cell therapy and 3D bioprinting — to reach clinical translation at qualified hospitals after demonstrating safety and preliminary efficacy.

- **LinkedIn (BetaLife SG), 2026-07:** [#ipsc #betalife #celltherapy #ipsc #regenerativemedicine #diabetes #clinicaltranslation #biotechnology #xiamen](https://www.linkedin.com/posts/betalife-sg_betalife-celltherapy-ipsc-activity-7487455334345834497-5hKR). Score 0.779. Explicitly references "Order No. 818, effective May 1, 2026. The regulation introduces an accelerated pathway for eligible advanced biomedical technologies towards regulated clinical translation at qualified hospitals after demonstrating safety and preliminary efficacy." BetaLife (a Singapore-based iPSC company) names this in their post; they cite it as directly relevant to their China clinical-translation journey.
- **Roots Analysis, 2026-07:** [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html). Score 0.669. Re-mention of the broader China cell-therapy regulatory landscape (Merck–Bio-Techne $11.3B acquisition, CARsgen China approval). Not an Order No. 818 citation directly, but corroborates the pattern of accelerating China cell-therapy regulatory activity in the same window.
- **Tavily answer text** independently synthesizes: "China's regulation under Order No. 818, effective May 1, 2026, introduces an accelerated pathway for advanced biomedical technologies, including cell therapy and 3D bioprinting, towards clinical translation at qualified hospitals after demonstrating safety and preliminary efficacy." This is the same content as the BetaLife post — single primary source, with Tavily's synthesis echoing it.

**Robin relevance:** HIGH for the Chinese pharma R&D / CDMO / biotech customer base. Order No. 818 is the **clinical-translation pathway** counterpart to the CDE classification item (which is about CMC planning). Both items matter: classification scope drives what dossier content vendors need to assemble, and the clinical-translation pathway drives which hospitals can host the first-in-human studies. Together they shape how Femtobiomed positions CelVivo-class bioreactors and 3Brain-class MEA platforms into Chinese accounts.

**Why source-backed (not watchlist):** the item is published regulatory text (Order No. 818, effective 2026-05-01), not a rumor; BetaLife is a credible industry-actor source citing it in their own clinical-translation context; the Tavily synthesis is consistent with the BetaLife wording. Treat as source-backed pending direct NMPA / State Council corroboration. **Promoted** to `/themes.md` as a new row `china-order-no-818-clinical-translation` and to `/commitments.md` as a verification item.

### LLM Wiki + OKF / shared-agent-memory cluster — source-backed (workflow tooling, low priority)

The `agent personal memory wiki 2026` query returned five same-week sources on a single coherent architecture: a shared agent-memory layer using Andrej Karpathy's LLM Wiki + Google's Open Knowledge Format (OKF) + Model Context Protocol (MCP), positioned to let "every Local AI … share ONE permanent memory." This is directly adjacent to OpenWiki's role.

- **YouTube (Kai), 2026-07-23:** [LLM Wiki + OKF Every Local AI Now Shares ONE Memory](https://www.youtube.com/watch?v=9ciGYHHOLyU). Score 0.752. Walkthrough of the LLM Wiki + OKF + MCP stack for cross-agent shared memory without vector databases.
- **Taskade AI, 2026-07:** [The 4 Types of AI Agent Memory Explained (2026)](https://www.taskade.com/wiki/ai-agents/memory-types). Score 0.705. Taskade's own memory architecture (long-term / episodic / short-term / semantic) framed in the same shared-memory terms.
- **GitHub (SamurAIGPT), 2026-07:** [SamurAIGPT/llm-wiki-agent](https://github.com/SamurAIGPT/llm-wiki-agent). Score 0.694. Open-source "personal knowledge base that builds and maintains itself" — wiki-ingest / wiki-query primitives that mirror Robin's OpenWiki mental model.
- **LinkedIn (David Bressler, PhD), 2026-07:** [Personal wikis, LLM-maintained knowledge bases, and agent memory systems all eventually hit the same question: How do you know the information in there is still accurate?](https://www.linkedin.com/posts/david-bressler_personal-wikis-llm-maintained-knowledge-activity-7486993623939678208-q4rL). Score 0.614. Adjacent commentary on knowledge-base freshness in agent-maintained wikis.
- **Reddit r/ClaudeAI, 2026-07-23:** [How many of you are running an LLM wiki with claude code?](https://www.reddit.com/r/ClaudeAI/comments/1v4rdiv/how_many_of_you_are_running_an_llm_wiki_with). Score 0.288 (31 upvotes, 26 comments). Community confirmation that OKF-formatted Obsidian wikis are a working pattern for Claude Code users.
- **BigDATAwire (Exabase), 2026-07-28:** [Exabase Reports State-of-the-Art Results on BEAM Memory Benchmark](https://www.hpcwire.com/bigdatawire/this-just-in/exabase-reports-state-of-the-art-results-on-beam-memory-benchmark). Score 0.567. Adjacent: BEAM-style memory benchmarks for agent memory engines.

**Robin relevance:** workflow-tooling, low priority — but the cluster is **substantially more corroborated than the prior HN-only signal**. Five distinct publishers (YouTube creator, SaaS vendor, GitHub, LinkedIn, Reddit) and one adjacent benchmark in the same week all converge on the same OKF + MCP shared-memory architecture. Combined with the existing `agent-memory-architecture` row's three HN Show HN items, the topic now has 8+ distinct sources. **Promote** `agent-memory-architecture` from `watchlist` to `source-backed` and refresh Last seen to 2026-07-28.

### 3Brain / Cellink / CellShot / installed-base / Hermes lanes — no new vendor-anchored evidence; Tavily answer-text mis-attribution recurs

- **3Brain CorePlate MEA 2026:** the Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187. Tavily answer text again labels it "3Brain CorePlate MEA 2026 validated in a brain–computer interface study" — the underlying paper is about a portable EEG headset, **not 3Brain's MEA chips**. This is the fourth pull in a row with the same mis-attribution. Do not promote as 3Brain evidence.
- **Cellink BIO X bioprinter 2026:** Tavily answer text labels the Roche [ADLM 2026 intelligent lab solutions press release](https://www.biospace.com/press-releases/roche-showcases-intelligent-lab-solutions-and-high-precision-instruments-at-adlm-2026-to-help-laboratories-address-workforce-and-workflow-challenges) (0.082) as "Cellink BIO X bioprinter at ADLM 2026" — the underlying source is Roche, not Cellink. The remainder of the lane is industry context (Nova Biomedical–NanoCellect, Massive Bio–GELL, Lumafield Mars X-ray, Repligen–BioLife, BioTechniques bi-weekly). All unrelated to Cellink BIO X / BIONOVA X / Lumen X.
- **CellShot / CellPick bioprinter 2026:** Tavily honestly says "the CellShot CellPick bioprinter 2026 is not directly mentioned in the provided data sources." Top hits are CCDx whole-cell genomic profiling (0.164), Nova Biomedical–NanoCellect (0.062), AI protein engineering model (0.059), Towards Healthcare cell-and-gene-therapy intelligence infrastructure (0.052), Pluristyx re-mention (0.042). No Femtobiomed vendor signal.
- **labs CelVivo ClinoStar installed base 2026:** no direct result. Cepheid GeneXpert third-generation ADLM 2026 (score 0.112) and Roche ADLM 2026 (0.143) dominate the top slots and are unrelated to CelVivo installed-base. Query phrasing continues to drift toward competitor/molecular-diagnostic content.
- **Hermes Agent MiniMax M3 changelog 2026:** Tavily answer text returns Apple product news ("Mismatched M6 and M5 Pro chips", iOS 26.6, POCO Launcher 7.50) — no Hermes Agent, no MiniMax M3, no Hermes changelog in the underlying URLs. Top hit: [MacRumors Next Mac Mini article](https://www.macrumors.com/2026/07/22/mac-mini-m6-m5-pro-chips-rumor/) at 0.074. The v0.19 Quicksilver signal from the prior pull remains the most recent Hermes row; this lane produced nothing new in this 24h window.
- **OpenWiki connectors Tavily RAGFlow 2026:** Tavily recall still broken. Returns AWWA ACE26 SmartBall X (0.025), Bizora advisory group / Billtrust MCP server (0.026), OpenTug shipping (0.017), Sunvega AI spatial-design workspace (0.016), RightShip maritime (0.016), Inland Tank-Barge Safety Guide (0.015). Only the Billtrust MCP server item is mildly adjacent (MCP-server ecosystem); the rest is unrelated to OpenWiki / Gitea / Wiki.js / RAGFlow / NocoDB / SeaFile. Recommend dropping this lane from future Tavily runs unless the query is rephrased to anchor on product names.
- **organ-on-chip pharma collaboration 2026:** the Nature [Gut-on-a-Chip culturomics paper](https://www.nature.com/articles/s44385-026-00099-1) (0.986) is the same item surfaced in the 2026-07-26 17:39 pull. Application-domain signal only — folds into the `class-organoid-3d-bioprinting` row without a new evidence note.

### Synthesis result

- **Two new scope-aligned findings:**
  1. **China Order No. 818** — clinical-translation pathway for cell therapy + 3D bioprinting at qualified hospitals, effective 2026-05-01. Source-backed on a single primary source (BetaLife LinkedIn) with Tavily synthesis corroboration. Distinct from the existing `china-cde-cell-gene-therapy-rules-2026` item (classification vs clinical pathway). Promoted to `/themes.md` as new row `china-order-no-818-clinical-translation` and to `/commitments.md` as a verification item.
  2. **LLM Wiki + OKF shared-memory cluster** — five Tavily sources + three prior HN sources all converge on Karpathy's LLM Wiki + Google OKF + MCP shared-memory architecture. Directly adjacent to OpenWiki's role. Promotes existing `agent-memory-architecture` row from `watchlist` to `source-backed`.
- **No new vendor-anchored evidence** on CelVivo, 3Brain, Cellink, CellShot/TriArm, or Hermes this pull. The prior vendor-anchored items (CelVivo+TheWell, Hermes v0.19 Quicksilver) remain on disk and referenceable; the Hermes row's Last seen is **not** refreshed because the underlying URLs in this pull returned Apple-product noise.
- **Tavily answer-text mis-attribution pattern persists** on 3Brain (4th pull), Cellink (4th pull), and Hermes (1st pull). This is a Tavily-side quality issue; treat Tavily answer text as untrusted and only the underlying URLs as evidence. Continued recommendation: narrow future pulls to vendor-name-anchored queries only.
- **OpenWiki / RAGFlow / agent-memory lane behavior changed.** The lane still produces zero OpenWiki/RAGFlow/SeaFile/NocoDB/Gitea results, but the **agent-personal-memory-wiki** lane is now high-signal for the OKF/LLM Wiki architecture — strong enough to promote the existing `agent-memory-architecture` row.